Rabbit Recombinant Monoclonal ErbB2 / HER2 antibody. Carrier free. Suitable for ELISA, WB, ICC/IF and reacts with Synthetic peptide, Human samples.
pH: 7.2 - 7.4
Constituents: PBS
Flow Cyt | ELISA | WB | ICC/IF | |
---|---|---|---|---|
Human | Not recommended | Expected | Tested | Tested |
Synthetic peptide | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Select an associated product type
The protein expressed by the ERBB2 gene is a protein tyrosine kinase involved in several cell surface receptor complexes, requiring a coreceptor for ligand binding. It is an essential component of a neuregulin-receptor complex, although neuregulins do not bind to it directly. GP30 is a potential ligand for this receptor. ERBB2 regulates the outgrowth and stabilization of peripheral microtubules (MTs) via the MEMO1-RHOA-DIAPH1 signaling pathway, which, upon activation, phosphorylates and inhibits GSK3B at the cell membrane. This prevents APC and CLASP2 phosphorylation, allowing their association with the cell membrane, facilitating MACF1 localization necessary for microtubule capture and stabilization. In the nucleus, ERBB2 is involved in transcriptional regulation, associating with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter to activate transcription. It is implicated in the transcriptional activation of CDKN1A, involving STAT3 and SRC, and participates in the transcription of rRNA genes by RNA Pol I, thereby enhancing protein synthesis and cell growth. This supplementary information is collated from multiple sources and compiled automatically.
CD340, HER2, MLN19, NEU, NGL, ERBB2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19
Rabbit Recombinant Monoclonal ErbB2 / HER2 antibody. Carrier free. Suitable for ELISA, WB, ICC/IF and reacts with Synthetic peptide, Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab245120 is the carrier-free version of Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The ErbB2 also known as HER2 or HER2 protein is a transmembrane receptor protein with a molecular weight of about 185 kDa. It serves as part of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. The ErbB2 protein is expressed mainly in epithelial tissues including those of the breast and the gastrointestinal tract. It lacks a known ligand-binding domain which sets it apart from other members of its family. Due to its structure ErbB2 dimerizes with other members of the EGFR family to exert its effects in cellular signaling.
The role of ErbB2 extends beyond a singular function. It becomes an active component when forming heterodimers with other EGFR family members such as ErbB3 to initiate various downstream signaling cascades. The dimerization activates intracellular pathways leading to cell proliferation survival differentiation and migration. Within cells ErbB2 influences processes critical for normal development and tissue homeostasis contributing significantly to signal transduction networks.
ErbB2 plays a pivotal role in pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are important in mediating cellular responses to growth signals. The PI3K/Akt pathway activated by HER2 signaling regulates cell growth and survival while the MAPK/ERK pathway contributes to cell differentiation and proliferation. ErbB2's interaction with proteins like ErbB3 is fundamental in these pathways increasing the amplitude and diversity of downstream signals.
ErbB2 is significantly associated with breast cancer and gastric cancer. The overexpression or gene amplification of HER2 is observed in approximately 20% of breast cancer cases correlating with aggressive tumor growth and poor prognosis. ErbB2-related signaling contributes to oncogenic processes by promoting excessive cell proliferation. Targeting ErbB2 in these cancers is common using therapies such as monoclonal antibodies like trastuzumab. In the context of gastric cancer the role of ErbB2 mirrors its function in breast cancer and targeting HER2 holds therapeutic potential.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
False colour image of Western blot: Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325 was shown to bind specifically to ErbB2 / HER2. A band was observed at 180 kDa in wild-type HeLa cell lysates with no signal observed at this size in ERBB2 knockout cell line ab255387 (knockout cell lysate ab263758). To generate this image, wild-type and ERBB2 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325).
All lanes: Western blot - Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] (Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 40 µg
Lane 2: ERBB2 knockout HeLa cell lysate at 40 µg
Performed under reducing conditions.
Predicted band size: 137 kDa
Immunofluorescent analysis of 100% methanol fixed SK-BR-3 (human breast adenocarcinoma epithelial cell) cells labeling ErbB2 / HER2 with Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325 at 1/50 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) secondary antibody at 1/1000 dilution (green).
Confocal image showing membranous staining in SK-BR-3 cells.
Negative control: MCF7 (Human breast adenocarcinoma cell line) (PMID:20697531). Negative staining was obtained from 4% PFA fixation.
The nuclear counter stain is DAPI (blue). Tubulin is detected with Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at a 1/200 dilution (red).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325).
50 ng CPTAC-36d (1000 ng/mL, 50 μL per well) was coated onto 96-wells. Serial dilutions (0, 0.2, 0.9, 3.9, 15, 62, 250, 1000 ng/mL) of Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325 (50 μL) were incubated with CPTAC-36d in each well for 60 minutes by shaking. This was followed by adding goat anti-rabbit IgG, (H+L), phosphatase-conjugated secondary antibody (50 μL, 1/2500) into each well and incubating for another 40 minutes. After washing, 50 μL of PNPP was added and incubated for 15 minutes without shaking for color development. OD was read at 405nm within 5 minutes.
Primary antibody concentration range: 0.01 - 1.0 μg/mL.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-ErbB2 / HER2 antibody [CPT-R32.2-27-12] ab241325).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com